Bio‑Techne’s Earnings Beat Sparks 11% After‑Hours Rally, Boosting Investor Confidence
Bio‑Techne’s earnings beat fuels an after‑hours rally, showing that a robust proteins & cytokines pipeline and upgraded guidance can lift a high‑PE biotech stock toward investor focus.
3 minutes to read